Lyell Immunopharma, Inc. (LYEL)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Biotechnology			84.68M	10.65M	7.76M	657.00K
Biotechnology Growth			695.15%	37.31%	1080.52%	-
Total			84.68M	10.65M	7.76M	657.00K
Total Growth			695.15%	37.31%	1080.52%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States			84.68M	10.65M	7.76M	657.00K
United States Growth			695.15%	37.31%	1080.52%	-
Total			84.68M	10.65M	7.76M	657.00K
Total Growth			695.15%	37.31%	1080.52%	-

Source: S&P Global Market Intelligence.